Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Lyons Gary A sold 15,000 Neurocrine Biosciences, Inc. shares (Form 4)
Traded Nov 17, 2026 · Filed Nov 19, 2026
On Nov 17, 2026, Lyons Gary A (Director) sold 15,000 Neurocrine Biosciences, Inc. shares at an average US$164.87 for US$2.47M under a trading plan, leaving 122,141 shares. Filed Nov 19, 2026 (Form 4).
- Sold
- 15,000 shares
- Price
- US$164.87 average (US$163.11 to US$165.90)
- Value
- US$2.47M
- Holding after
- 122,141 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Common Stock | Option exercise | 15,000 | US$53.64 | 137,141 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 1,200 | US$163.11 | 135,941 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 4,011 | US$163.94 | 131,930 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 5,689 | US$165.15 | 126,241 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 4,100 | US$165.90 | 122,141 | Direct |
Source
Download original · View original at SEC
Related
- Neurocrine Biosciences, Inc.
- Lyons Gary A
- Neurocrine Biosciences, Inc. shareholders
- Form 4 · Lyons Gary A · May 21, 2026
- Form 4 · Morrow George J · Nov 3, 2026
- Form 4 · Gano Kyle · Nov 3, 2026
- Schedule 13G · Vanguard Portfolio Management LLC · Oct 30, 2026
- Schedule 13G/A · JPMorgan Chase & Co · Oct 15, 2026
- Form 4 · Abernethy Matt · Sep 15, 2026